• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

TargeGen

edit

TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions. It serves macular degeneration, diabetic macular edema, and diabetic retinopathy markets.

The company was founded in 2002 and is based in San Diego, California. It was acquired by Sanofi Aventis in 2010.

Milestones

edit

• 
  TargeGen added Wood C. Erwin as CFO.
  Posted 6/30/10 at 5:53pm
• 
  TargeGen added Peter G. Ulrich as Co-Founder, President & CEO.
  Posted 6/30/10 at 5:53pm
• 
  TargeGen was acquired by Sanofi Aventis for $635M. (6/30/10)
  Posted 6/30/10 at 5:54pm via fiercebiotech.com

Videos

Screenshots

edit

Sources

1. On a spree, Sanofi scoops up TargeGen in $635M dea Read more: On a spree, Sanofi scoops up TargeGen in $635M deal (fiercebiotech.com) [edit]